Detalles de la búsqueda
1.
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.
Breast Cancer Res Treat
; 204(2): 299-308, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38175448
2.
Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
BMC Cancer
; 23(1): 738, 2023 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37563628
3.
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.
BMC Cancer
; 22(1): 322, 2022 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35331169
4.
Previously diagnosed multiple primary malignancies in patients with breast carcinoma in Western Sweden between 2007 and 2018.
Breast Cancer Res Treat
; 184(1): 221-228, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32740808
5.
The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
BMC Cancer
; 19(1): 187, 2019 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30819139
6.
Breast cancer survival trends in different stages and age groups - a population-based study 1989-2013.
Acta Oncol
; 58(1): 45-51, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30513223
7.
Immune gene expression and response to chemotherapy in advanced breast cancer.
Br J Cancer
; 118(4): 480-488, 2018 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29370583
8.
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Breast Cancer Res Treat
; 161(1): 117-134, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27796716
9.
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
JAMA
; 313(13): 1347-61, 2015 Apr 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-25849179
10.
Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.
medRxiv
; 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38496424
11.
High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
BMC Cancer
; 13: 47, 2013 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23374458
12.
Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome.
BMC Cancer
; 13: 1, 2013 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-23282137
13.
Survivin promotes a glycolytic switch in CD4+ T cells by suppressing the transcription of PFKFB3 in rheumatoid arthritis.
iScience
; 25(12): 105526, 2022 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36425763
14.
Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.
Cancers (Basel)
; 13(9)2021 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34064473
15.
Genetic alterations associated with multiple primary malignancies.
Cancer Med
; 10(13): 4465-4477, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34057285
16.
Long-Term Prognostication for 20 114 Women With Small and Node-Negative Breast Cancer (T1abN0).
JNCI Cancer Spectr
; 5(1)2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33442658
17.
A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.
Sci Rep
; 11(1): 14763, 2021 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34285278
18.
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
JAMA Oncol
; 7(9): 1360-1367, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34165503
19.
Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).
Breast Cancer Res Treat
; 123(3): 785-93, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20680680
20.
BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Acta Oncol
; 49(3): 361-7, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20151938